Literature DB >> 15920296

Complement protein isoforms in CSF as possible biomarkers for neurodegenerative disease.

Erin J Finehout1, Zsofia Franck, Kelvin H Lee.   

Abstract

It has been suggested that the activation of the complement system is involved in the pathogenesis of several neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and multiple sclerosis (MS). Here, the CSF expression levels of complement proteins C3b, C4b, factor B, and factor H were compared between normal subjects and patients diagnosed with AD, PD, MS, and neurosyphilis. The CSF proteins were initially separated using two-dimensional gel electrophoresis, which allowed the comparison of some of the individual complement isoforms. Patients with AD, PD, and MS all showed more than one complement isoform with a significant change (p < 0.05) in CSF expression level compared to normal subjects. PD patients were found to have the greatest number of significantly changed isoforms, all showing a decreased expression level in PD CSF. The complement isoforms examined were able to distinguish between some, but not all, of the diseases studied. The data suggest that when investigating a protein as a possible biomarker, it may be useful to compare individual protein isoform expression levels in addition to the more commonly measured total protein expression level.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15920296      PMCID: PMC3851089          DOI: 10.1155/2005/806573

Source DB:  PubMed          Journal:  Dis Markers        ISSN: 0278-0240            Impact factor:   3.434


  26 in total

Review 1.  Neuroproteomics as a promising tool in Parkinson's disease research.

Authors:  Ilse S Pienaar; William M U Daniels; Jürgen Götz
Journal:  J Neural Transm (Vienna)       Date:  2008-06-04       Impact factor: 3.575

2.  Global protein differential expression profiling of cerebrospinal fluid samples pooled from Chinese sporadic CJD and non-CJD patients.

Authors:  Cao Chen; Di Xiao; Wei Zhou; Qi Shi; Hui-Fang Zhang; Jin Zhang; Chan Tian; Jian-Zhong Zhang; Xiao-Ping Dong
Journal:  Mol Neurobiol       Date:  2013-08-04       Impact factor: 5.590

Review 3.  Two-dimensional protein electrophoresis: from molecular pathway discovery to biomarker discovery in neurological disorders.

Authors:  Leila H Choe; Brenda G Werner; Kelvin H Lee
Journal:  NeuroRx       Date:  2006-07

4.  Longitudinal effects of intravenous immunoglobulin on Alzheimer's cerebrospinal fluid proteome.

Authors:  Gilda Shayan; Basia Adamiak; Leila H Choe; Norman Relkin; Kelvin H Lee
Journal:  Electrophoresis       Date:  2014-07       Impact factor: 3.535

Review 5.  Let's make microglia great again in neurodegenerative disorders.

Authors:  Marie-Victoire Guillot-Sestier; Terrence Town
Journal:  J Neural Transm (Vienna)       Date:  2017-10-12       Impact factor: 3.575

Review 6.  Proteomics in Human Parkinson's Disease: Present Scenario and Future Directions.

Authors:  Anubhuti Dixit; Rachna Mehta; Abhishek Kumar Singh
Journal:  Cell Mol Neurobiol       Date:  2019-06-12       Impact factor: 5.046

7.  Interleukin 6 and complement serum level study in Parkinson's disease.

Authors:  Branislav Veselý; Michal Dufek; Vojtech Thon; Miroslav Brozman; Silvia Királová; Tatiana Halászová; Eva Koriťáková; Ivan Rektor
Journal:  J Neural Transm (Vienna)       Date:  2018-02-12       Impact factor: 3.575

Review 8.  Biomarker modelling of early molecular changes in Alzheimer's disease.

Authors:  Ross W Paterson; Jamie Toombs; Catherine F Slattery; Jonathan M Schott; Henrik Zetterberg
Journal:  Mol Diagn Ther       Date:  2014-04       Impact factor: 4.074

9.  Structural and quantitative comparison of cerebrospinal fluid glycoproteins in Alzheimer's disease patients and healthy individuals.

Authors:  Carina Sihlbom; Pia Davidsson; Magnus Sjögren; Lars-Olof Wahlund; Carol L Nilsson
Journal:  Neurochem Res       Date:  2008-02-21       Impact factor: 3.996

Review 10.  Complement in multiple sclerosis: its role in disease and potential as a biomarker.

Authors:  G Ingram; S Hakobyan; N P Robertson; B P Morgan
Journal:  Clin Exp Immunol       Date:  2008-11-24       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.